 Shares of Miromatrix Medical Inc. were down about 33 in premarket trading on Thursday, the day after the company said theres a clinical hold on its experimental acute liver failure treatment. Miromatrix had submitted the investigational new drug application for the therapy to the Food and Drug Administration last month. 